KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Non-Current Liabilities: 2024

Historic Total Non-Current Liabilities for Recursion Pharmaceuticals (RXRX) over the last 1 years, with Dec 2024 value amounting to $409.1 million.

  • Recursion Pharmaceuticals' Total Non-Current Liabilities rose 76.71% to $351.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $351.5 million, marking a year-over-year increase of 76.71%. This contributed to the annual value of $409.1 million for FY2024, which is N/A change from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $409.1 million for FY2024.
  • In the past 5 years, Recursion Pharmaceuticals' Total Non-Current Liabilities registered a high of $409.1 million during FY2024, and its lowest value of $409.1 million during FY2024.
  • Moreover, its 1-year median value for Total Non-Current Liabilities was $409.1 million (2024), whereas its average is $409.1 million.